Drug Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

The correct mix of excipients is crucial to the success of fast dissolving/orally disintegrating dosage forms.

Formulating for Convenience and Compliance

Bioanalytical studies are an important aspect of biologic drug development that may necessitate partnering with bioanalysis experts.

The Importance of Partnering for Bioanalytical Studies

Survey results indicate that the current regulatory approval pathway for excipients creates a challenge for the use of novel excipients.

USP Novel Excipients Survey: Stakeholders’ Views on the Current State of Excipient Innovation

The companies have formed a collaboration to develop a novel human recombinant protein as a therapeutic candidate against COVID-19.


Airway Therapeutics, Celonic Group Partner on New COVID-19 Therapeutic

CanSinoBIO will license-in Precision NanoSystems' proprietary RNA vaccine platform technology while the latter leads the development of the RNA vaccine formulation.

CanSino Biologics, Precision NanoSystems to Co-develop COVID-19 RNA Vaccine

HHS announces $354 million in funding for private industry to manufacture generic drugs in the US from raw materials to finished product.

BARDA Funds US-based Drug Manufacturing Initiative

Quartic.ai and Bright Path Laboratories have agreed to develop an artificial intelligence (AI)-powered continuous manufacturing platform for APIs and other small-molecule drugs using Bright Path Labs’ continuous bioreactor and the Quartic.ai smart manufacturing technology.

Quartic.ai and Bright Path Labs Will Use AI for API Continuous Manufacturing

Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks? 

Formulating an ADC Development Solution

Agnes Shanley is senior editor of Pharmaceutical Technology.

Discovery of carcinogenic nitrosamines in three of the world’s most widely prescribed drugs is driving efforts to better detect, control and prevent their generation in APIs and finished drug products.


Contamination Drives a More Concerted Approach to Genotoxins

Wavelength Pharmaceuticals expanded production of APIs for certain pharmaceutical products needed to manage respiratory critical care patients in the COVID-19 pandemic.

APIs and Excipients